Revelation Biosciences, Inc. Common Stock (REVB)
PHARMACEUTICAL PREPARATIONS
Revelation Biosciences, Inc. Common Stock (REVB) is listed on Nasdaq, where it has traded since January 11, 2022.
- Listed On
- Nasdaq
- Listed Since
- January 11, 2022
- Employees
- 9
- Market Cap
- $3M
About Revelation Biosciences, Inc. Common Stock
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 13 institutions reported holding REVB, with 304,296 shares worth $313,166 in aggregate. The largest reported holder was Sabby Management, with 210,582 shares worth $216,899. Of the 5 largest holders listed below, 2 opened new positions in REVB, 1 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Sabby Management | 210,582 | $217K | Added 111.78% |
| Citadel Advisors | 38,579 | $40K | New position |
| Geode Capital Management | 17,192 | $18K | Reduced 60.2% |
| Hrt Financial | 16,978 | $17K | New position |
| Vanguard | 13,127 | $14K | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is REVB?
Revelation Biosciences, Inc. Common Stock (REVB) is listed on Nasdaq, where it has traded since January 11, 2022.
Who are the largest institutional holders of REVB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of REVB were Sabby Management, Citadel Advisors and Geode Capital Management.
How many institutions own REVB?
13 institutions reported a position in REVB for the quarter ended June 30, 2026, worth $313,166 in total.
Did institutions buy or sell REVB last quarter?
Of the 5 largest reported holders, 2 opened new positions in REVB, 1 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for REVB.
Every reported institutional holder, plus insider and congressional trades in REVB, on SentiSense.